Wat is de prijs voor ZIOPHARM Oncology, Inc. (ZIOP)

Het prijs van ZIOPHARM Oncology, Inc. (ZIOP) is $0.8657

Wat is de marktkapitalisatie voor ZIOPHARM Oncology, Inc. (ZIOP)

Marktkapitalisatie voorZIOPHARM Oncology, Inc. (ZIOP) is $122.22M

ZIOPHARM Oncology, Inc. (ZIOP) K/B-verhouding

ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.

Jaar	P/B-ratio	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

P/B-ratio

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	P/B-ratio	Verschil in P/B-ratio	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

P/B-ratio

Verschil in P/B-ratio

Land